Efficacy prediction for the virtual patient cohort generated based on calibrated parameter distribution
| Variable | Nab-paclitaxel | Atezolizumab/nab-paclitaxel |
| Response | ||
| Number of virtual patients | 450 | 450 |
| Objective response | ||
| No. of patients (median) | 209 | 266 |
| % of patient (95 bootstrap percentile) | 46.4 (41.0–52.0) | 59.1 (53.2–64.7) |
| Complete response | ||
| No. of patients (median) | 9 | 11 |
| % of patient (95 bootstrap percentile) | 2.0 (0.7–3.9) | 2.4 (0.9–4.4) |
| Partial response | ||
| No. of patients (median) | 200 | 255 |
| % of patient (95 bootstrap percentile) | 44.4 (38.9–50.7) | 56.7 (50.6–62.2) |
| Stable disease | ||
| No. of patients (median) | 138 | 106 |
| % of patient (95 bootstrap percentile) | 30.7 (25.7–36.2) | 23.6 (18.7–28.2) |
| Progressive disease | ||
| No. of patients (median) | 103 | 78 |
| % of patient (95 bootstrap percentile) | 22.9 (18.2–27.6) | 17.3 (13.1–21.6) |
| Duration of response | ||
| Number of virtual patients | 209 | 266 |
| Median duration of response in months (95 bootstrap percentile) | 5.6 (5.6–7.5) | 7.5 (5.6–9.3) |
| No. of virtual patients with ongoing response after 400 days of treatment in model simulations (%) | 69 (33.2) | 87 (32.7) |
Bootstrap median and CIs are reported.